Which of the following is a JC accountability measure for children with asthma inpatients?

• A. Systemic steroids for inpatients
• B. Daily inhaled beta-agonist before discharge
• C. Immunization status only
• D. Home management/Care plan

Answer: (B)

Joint Commission accountability measures for pediatric asthma focus on concrete, verifiable actions during a hospital stay that demonstrate quality care. For children admitted with asthma, one key measure is ensuring that a daily inhaled beta-agonist is used before discharge. This reflects that the child has been stabilized with bronchodilation during the hospitalization and is leaving the hospital with evidence of ongoing symptom relief and a plan for continued rescue therapy if needed. It also supports safe discharge by showing the care team has actively managed the acute episode and prepared the family to continue appropriate inhaled-therapy use at home.

Inhaled beta-agonists are central to acute asthma management, and documenting daily use before discharge helps confirm an adequate response to treatment and readiness to transition care. Systemic steroids are important during exacerbations but are not, by themselves, a discharge-quality metric in this context. Immunization status is important preventive care but does not specifically capture inpatient asthma management quality. A home management/care plan is valuable, but the measure highlighted here specifically targets the immediate inpatient process of ensuring bronchodilator therapy is appropriately addressed before discharge.